| [1] Janssens S，Beyaert R. Role of Toll-like receptors in pathogen recognition[J]. Clin Microbiol Rev，2003，16(4)：637-646.[2] Akira S，Uematsu S，Takeuchi O. Pathogen recognition and innate immunity[J]. Cell，2006，124(4)：783-801.[3] Akira S，Takeda K，Kaisho T. Toll-like receptors：critical proteins linking innate and acquired immunity[J]. Nature Immunol，2001，(2)8：675-680.[4] Huang B，Zhao J，Li H，et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance[J]. Cancer Res，2005，65(12)：5009-5014.[5] Cherfils-Vicini J，Platonova S，Gillard M，et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance[J]. J Clin Invest，2010， 120(4)：1285-1297.[6] Schmausser B，Andrulis M，Endrich S，et al. Toll-like receptors TLR4，TLR5 and TLR9 on gastric carcinoma cells：An implication for interaction with Helicobacter pylori[J]. Int J Med Microbiol，2005，295(3)：179-185.[7] Szczepanski M，Stelmachowska M，Stryczynski L，et al. Assessment of expression of toll-like receptors 2，3 and 4 in laryngeal carcinoma[J]. Eur Arch Otorhinolaryngol，2007， 264(5)：525-530.[8] Cai Z，Sanchez A，Shi Z，et al. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth[J]. Cancer Res，2011，71(7)： 2466-2475.[9] Kim WY， Lee JW，Choi JJ，et al. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia[J]. Int J Gynecol Cancer，2008，18：300-305.[10] Zhou M，McFarland-Mancini MM，Funk HM，et al. Toll-like receptor expression in normal ovary and ovarian tumors[J]. Cancer Immunol Immunother，2009，58(9)：1375-1385.[11] Garay，RP，Viens R，Bauer J，et al. Cancer relapse under chemotherapy：why TLR2/4 receptor agonist can help[J]. Eur J Pharmacol，2007，563(1)：1-17.[12] Krieg AM. Development of TLR9 agonists for cancer therapy[J]. J Clin Invest，2007，117(5)：1184-1194.[13] Fukata M，Hernandez Y，Conduah D，et al. Innate immune signaling by Toll-like receptor-4 (TLR4)shapes the inflammatory microenvironment in colitis-associated tumors[J]. Inflamm Bowel Dis，2009，15(7)：997-1006.[14] 黄 华. Toll样受体4基因(TLR4)多态性与胃癌易感性的关联研究[D]. 南京：南京医科大学，2010.[15] 张 丽. 中国汉族人群单核苷酸多态性与幽门螺杆菌相关性胃癌的关系研究[D]. 重庆：重庆医科大学，2011.[16] Achyut BR，Ghoshal UC，Moorchung N，et al. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions[J]. Hum Immunol，2007，68(11)：901-907.[17] Santini D，Angeletti S，Ruzzo A，et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes[J]. Clin Exp Immunol，2008， 154(3)：360-364.[18] Tahara T，Arisawa T，Wang F，et al. Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Japanese people to gastric cancer[J]. Cancer Sci，2007， 98(11)：1790-1794.[19] Hold GL，Rabkin CS，Gammon MD，et al. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations[J]. Eur J Cancer Prev， 2009 ，18(2)：117-119.[20] 陈丽珊， 郭秋莎， 夏 冰. CD14及TLR4基因多态性与大肠癌的相关性研究[C]. 中华医学会第七次全国消化病学术会议论文汇编(下册)： 中华医学会消化病学分会，2007：1.[21] 蒋 益， 闵小彦， 高劲松. Toll样受体4基因-299位点A/G多态性与溃疡性结肠炎及大肠腺癌的关系[J]. 长沙医学院学报，2007，2(1)：13-17.[22] Castro FA，F?rsti A，Buch S，et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer[J]. Eur J Cancer，2011，47(8)：1203-1210.[23] 陈小军. IL12A、IL12B和TLR9基因多态性与宫颈癌易感性的关联研究[D]. 南京：南京医科大学，2009.[24] Pandey S，Mittal RD，Srivastava M，et al. Impact of Toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly， Thr399Ile) in cervical cancer susceptibility in North Indian women [J]. Gynecol Oncol，2009，114(3)：501-505.[25] Pandey S，Mittal B，Srivastava M，et al. Evaluation of Toll-like receptors 3(c.1377C/T) and 9(G2848A) gene polymorphisms in cervical cancer susceptibility[J]. Mol Biol Rep，2011， 38(7)：4715-4721.[26] Priyadarshini A，Chakraborti A，Mandal AK，et al. Asp299Gly and Thr399Ile polymorphism of TLR-4 gene in patients with prostate cancer from North India[J]. Indian J Urol，2013，29(1)：37-41.[27] Mandal RK，George GP，Mittal RD. Association of Toll-like receptor (TLR) 2，3 and 9 genes polymorphism with prostate cancer risk in North Indian population[J]. Mol Biol Rep， 2012，39(7)：7263-7269.[28] Stark JR，Wiklund F，Gr?nberg H，et al. Toll-like receptor signaling pathway variants and prostate cancer mortality[J]. Cancer Epidemiol Biomarkers Prev，2009，18(6)：1859-1863.[29] Srivastava K，Srivastava A，Kumar A，et al. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer[J]. Liver Int，2010，30(7)：1067-1072.[30] 范 蕾. 研究TLR3及其介导通路在乳腺癌发生发展中的地位[D]. 上海：复旦大学， 2010.[31] 邹立君，张合喜，王友洁，等. TLR9基因多态性与肺癌易感性的关系[J]. 环境与职业医学，2006，1：8-10.[32] Gast A，Bermejo JL，Claus R，et al. Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival[J]. PLoS One，2011，6(9)：24370.[33] Kim SK，Park HJ，Hong IK，et al. A missense polymorphism (rs11466653，Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population[J]. Endocrine，2013，43(1)：161-169. |
